There are currently 89 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
NCT00001246
Recruiting
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution. Functional MRIs are diagnostic tests that allow doctors to not only view anatomy, but physiology and function. It is for these reasons that MRIs are excellent methods for studying the brain. In this study, researchers will use MRI to assess brain anatomy and function in X and Y chromosome variation... Read More
Gender:
ALL
Ages:
Between 3 years and 120 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder
Register for Updates
Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)
NCT04143126
Recruiting
This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/08/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Schizophrenia
Register for Updates
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190
Recruiting
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: University of California, Los Angeles, Los Angeles, California +6 locations
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Sun Valley Behavioral Med Center, Imperial, California +36 locations
Conditions: Schizophrenia
Register for Updates
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210
Recruiting
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/07/2025
Locations: Clinical Site, Phoenix, Arizona +49 locations
Conditions: Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Register for Updates
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876
Recruiting
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syn... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/07/2025
Locations: Clinical Site, Little Rock, Arkansas +24 locations
Conditions: Schizophrenia
Register for Updates
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
NCT06058702
Recruiting
Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher potency of cannabis, the availability of highly potent cannabinoid products, the commercialization of cannabis, and the rising rates of cannabis use, it is critical to understand how genetic factors influen... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
07/01/2025
Locations: West Haven Veterans Affairs Medical Center, West Haven, Connecticut
Conditions: Schizophrenia, Cannabis Use Disorder
Register for Updates
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034
Recruiting
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/25/2025
Locations: Neurocrine Clinical Site, Little Rock, Arkansas +5 locations
Conditions: Schizophrenia
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Alea Research, Phoenix, Arizona +174 locations
Conditions: Schizophrenia
Register for Updates
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
NCT05276050
Recruiting
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS and/or follow-ups.
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
06/09/2025
Locations: The University of Texas Health Science Center, Houston, Houston, Texas
Conditions: Smoking Cessation, Nicotine Addiction, Schizophrenia
Register for Updates
Song-making In a Group (SING)
NCT05929352
Recruiting
The overarching aim of the proposed work is to align a promising treatment lead - Musical Intervention (MI) - with a promising mechanistic account of psychosis - Predictive Processing. This protocol focuses on the R33 phase, to optimize its administration (Is active participation more effective than passive listening? Does creation of new music help more than performing others' creations?). By tracking the interrelation between symptom mechanisms and MI, the investigators can use those metrics t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2025
Locations: Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
Conditions: Schizophrenia
Register for Updates
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)
NCT06961916
Recruiting
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil combined with cognitive training for improving white matter integrity.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2025
Locations: The University of Texas Health Science Center, Houston, Houston, Texas
Conditions: Schizophrenia
Register for Updates